Antineoplastic Agents

"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Descriptor ID	D000970
MeSH Number(s)	D27.505.954.248
Concept/Terms	Antineoplastic Agents Antineoplastic Agents Agents, Antineoplastic Antineoplastic Drugs Drugs, Antineoplastic Antineoplastics Chemotherapeutic Anticancer Drug Drug, Chemotherapeutic Anticancer Antitumor Drugs Drugs, Antitumor Cancer Chemotherapy Agents Agents, Cancer Chemotherapy Chemotherapy Agents, Cancer Cancer Chemotherapy Drugs Chemotherapy Drugs, Cancer Drugs, Cancer Chemotherapy Chemotherapeutic Anticancer Agents Agents, Chemotherapeutic Anticancer Anticancer Agents Agents, Anticancer Antitumor Agents Agents, Antitumor

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.

Bar chart showing 618 publications over 30 distinct years, with a maximum of 49 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	0	1	1
1997	3	1	4
1998	2	0	2
1999	1	1	2
2000	5	2	7
2001	8	1	9
2002	9	3	12
2003	11	8	19
2004	10	9	19
2005	8	10	18
2006	12	5	17
2007	22	5	27
2008	19	8	27
2009	10	7	17
2010	24	12	36
2011	20	11	31
2012	15	10	25
2013	26	9	35
2014	40	9	49
2015	36	8	44
2016	18	11	29
2017	30	5	35
2018	30	6	36
2019	23	4	27
2020	21	4	25
2021	19	6	25
2022	19	1	20
2023	11	0	11
2024	3	5	8

Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.

M?rquez-Garb?n DC, Yanes CD, Llarena G, Elashoff D, Hamilton N, Hardy M, Wadehra M, McCloskey SA, Pietras RJ. Manuka Honey Inhibits Human Breast Cancer Progression in Preclinical Models. Nutrients. 2024 Jul 22; 16(14).

View in: PubMed
Borrego EA, Guerena CD, Schiaffino Bustamante AY, Gutierrez DA, Valenzuela CA, Betancourt AP, Varela-Ramirez A, Aguilera RJ. A Novel Pyrazole Exhibits Potent Anticancer Cytotoxicity via Apoptosis, Cell Cycle Arrest, and the Inhibition of Tubulin Polymerization in Triple-Negative Breast Cancer Cells. Cells. 2024 Jul 20; 13(14).

View in: PubMed
Adekiya TA, Hudson T, Bakare O, Ameyaw EE, Adebayo A, Olajubutu O, Adesina SK. PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer. Biomed Pharmacother. 2024 Aug; 177:117125.

View in: PubMed
Abu Rabe D, Chdid L, Lamson DR, Laudeman CP, Tarpley M, Elsayed N, Smith GR, Zheng W, Dixon MS, Williams KP. Identification of Novel GANT61 Analogs with Activity in Hedgehog Functional Assays and GLI1-Dependent Cancer Cells. Molecules. 2024 Jun 28; 29(13).

View in: PubMed
Luque JS. Discussions on Medical Cannabis: Addressing Missed Opportunities in Cancer Education. J Cancer Educ. 2024 Jun; 39(3):217-219.

View in: PubMed
Islam JY, Hathaway CA, Hume E, Turner K, Hallanger-Johnson J, Tworoger SS, Camacho-Rivera M. Characteristics of Patients With Cancer and COVID-19 Who Discontinued Cancer Treatment. JAMA Netw Open. 2024 May 01; 7(5):e2411859.

View in: PubMed
Wang S, Wang J, Lu X, Liu M, Liu Y, Li M, Kong X, Wu L, Guan Q, Zhang W. Design, synthesis and biological evaluation of novel tubulin-targeting agents with a dual-mechanism for polymerization inhibition and protein degradation. Eur J Med Chem. 2024 Jun 05; 272:116458.

View in: PubMed
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, Bargonetti J. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024 Mar 01; 584:216608.

View in: PubMed
Kumar R, Afrin H, Bhatt HN, Beaven E, Gangavarap A, Esquivel SV, Zahid MI, Nurunnabi M. Mucoadhesive Carrier-Mediated Oral Co-delivery of Bcl2 Inhibitors Improves Gastric Cancer Treatment. ACS Appl Mater Interfaces. 2024 Jan 10; 16(1):305-317.

View in: PubMed
Swain RM, Sanchez A, Gutierrez DA, Varela-Ramirez A, Aguilera RJ. Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells. PLoS One. 2023; 18(12):e0295441.

View in: PubMed

People

Explore

Similar Concepts

Top Journals